We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Liquidia Technologies Inc (LQDA) COM USD0.001

Sell:$4.06 Buy:$4.18 Change: $0.07 (1.67%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.07 (1.67%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.07 (1.67%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Liquidia Corp operates through it's subsidiaries, Liquidia Technologies, Inc. and RareGen, LLC (RareGen). The Company, through Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical company focused on the development and commercialization of products using it's PRINT technology. It is focused on developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. RareGen provides commercialization for rare disease pharmaceutical products, such as generic Remodulin (treprostinil) for pulmonary arterial hypertension. Treprostinil can be administered as a continuous infusion through the use of an infusion pump or continuous intravenous infusion through the use of a central venous catheter.

Contact details

P.O. Box 110085
United States
+1 (919) 3284400

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$217.27 million
Shares in issue:
51.98 million
United States
US dollar

Key personnel

  • Damian deGoa
    Chief Executive Officer, Director
  • Michael Kaseta
    Chief Financial Officer
  • Robert Lippe
    Chief Operations Officer
  • Scott Moomaw
    Senior Vice President - Commercial
  • Russell Schundler
    General Counsel, Secretary
  • Tushar Shah
    Chief Medical Officer, Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.